Pradaxa® – Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations
5 November 2012 | By Boehringer Ingelheim
New findings presented...
List view / Grid view
News
FDA and EMA reaffirm important health benefits and safety of Pradaxa® for patients with atrial fibrillation
5 November 2012 | By Boehringer Ingelheim
"We welcome the positive conclusions reached..."
Novartis drug Votubia® approved in the EU as first medication to treat patients with non-cancerous kidney tumors associated with TSC
5 November 2012 | By Novartis
European Commission approval for Votubia®...
IFPAC-2013: The Premier International Event on QbD and PAT
5 November 2012 | By IFPAC
IFPAC 2013, 22-25 January 2013, Baltimore Marriott Waterfront, Baltimore, Maryland, USA
Phase 3 Sensipar® / Mimpara® EVOLVE(TM) trial published in the New England Journal of Medicine
3 November 2012 | By Amgen
Study results presented at American Society of Nephrology's Kidney Week...
Merck will initiate interferon-free Phase II clinical trials for MK-5172
2 November 2012 | By Merck
Merck announced plans to initiate two new clinical trials with MK-5172...
Amgen to present data from four Phase 2 studies at upcoming American Heart Association Scientific Sessions 2012
2 November 2012 | By Amgen
Amgen to present data from four Phase 2 trials...
Abbott and the Abbott Fund donate $1 million in funding and products to support Hurricane Sandy relief efforts
2 November 2012 | By Abbott
Abbott and its foundation are providing $1 million in funding and product donations...
GSK announces FDA Advisory Committee vote in favour of raxibacumab for the treatment of inhalational anthrax infection
2 November 2012 | By GlaxoSmithKline
Anthrax has been identified as a serious potential threat...
Portola, Bristol-Myers Squibb and Pfizer sign clinical collaboration agreement
1 November 2012 | By Bristol-Myers Squibb Company
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer announced a clinical collaboration agreement...
Data in NEJM show Novartis drug Aclasta® significantly reduced the risk of fracture in men with osteoporosis with once-yearly infusion
1 November 2012 | By Edelman
NEJM published results...
More than £1 billion to be invested in UK science and research
1 November 2012 | By BIS Press Office
New science investment will make sure UK competes and thrives in global race...
Bristol-Myers Squibb receives positive decision from NICE for YERVOY® (ipilimumab)
1 November 2012 | By Bristol-Myers Squibb Company
NICE has decided to recommend YERVOY®...
GSK supports BMJ commitment on clinical trial data transparency
31 October 2012 | By GlaxoSmithKline
“GSK fully supports the commitment made by BMJ to drive greater transparency of clinical trial data..."
Wealth of worldwide evidence on Pradaxa® including first clinical data on long-term efficacy and safety of a novel oral anticoagulant to be presented
31 October 2012 | By Boehringer Ingelheim
Results from RELY-ABLE®...
